Vaccine Pause Sends LA Officials Scrambling

Keerthi Vedantam

Keerthi Vedantam is a bioscience reporter at dot.LA. She cut her teeth covering everything from cloud computing to 5G in San Francisco and Seattle. Before she covered tech, Keerthi reported on tribal lands and congressional policy in Washington, D.C. Connect with her on Twitter, Clubhouse (@keerthivedantam) or Signal at 408-470-0776.

Vaccine Pause Sends LA Officials Scrambling
Photo by Mat Napo on Unsplash

Los Angeles is scrambling to deal with the federal health officials' call for a pause in the use of single-dose Johnson & Johnson vaccines that have helped speed up local inoculations.

L.A. Mayor Eric Garcetti said city-run vaccination sites had more than 3,000 patient appointments scheduled for Tuesday that will now receive a first dose of Pfizer, instead of the planned Johnson & Johnson vaccine. It comes two days after Los Angeles County opened vaccinations to everyone 16 and older.


In Long Beach, officials said those with an appointment at mobile clinics where the Johnson & Johnson vaccine was scheduled to be given will be contacted and offered either a Pfizer and Moderna vaccination. So far, no local cases of the rare blood clotting that forced federal officials to stop use of the vaccination have been reported, Long Beach officials said in a statement.

The move comes after the Center for Disease Control (CDC) and the Food and Drug Administration (FDA) reported six cases of blood clots among individuals who received one of the 6.8 million Johnson and Johnson vaccines distributed nationally.

Already, 900,000 of the vaccines have been distributed to people in California, making up roughly 40% of all vaccinated adults in the state. But, Gov. Gavin Newsom said on Twitter Tuesday that only 4% of the state's current supply is Johnson and Johnson.

In a joint statement, the CDC and the FDA said the recommendation to pause the vaccines was made "out of an abundance of caution." The agencies will use this time to understand and prepare treatments for these blood clots.

"The system is working as it should," said Shira Shafir, a public health professor at UCLA. "If we suspect something might be happening, then we do evaluate whether or not we have enough information."

Shafir said the CDC and FDA may decide to update recommendations to better avoid the serious blood clots. Neither agency has determined that the vaccine does cause the blood clots.

The move will largely impact vulnerable populations, such as those who are homebound or live in rural areas, or who cannot take time off work.

That's because the Johnson & Johnson vaccine did not need to be stored in sub-zero temperatures like Moderna and Pfizer vaccines and is administered in a single shot.

Get Out the Shot, a 400-person volunteer program in Los Angeles dedicated to booking vaccine appointments for people who may not have proper documentation or have a language barrier, are informing people if there is a vaccine change.

"One of the big concerns with a lot of the people that we're helping is the wage loss that accompanies time off in order to get to that vaccine appointment," said founder Liz Schwandt. "So we don't want to have to double someone's time that they have to spend away from providing care for their families or from working."

But, Schwandt said, smaller community clinics who cannot pivot quickly to a different vaccine are cancelling appointments, making it difficult for people who took time off work to recoup those lost wages.

It is unclear if this will affect California's goal of opening its economy June 15, though the California Department of Public Health said in a press release, "we do not expect a significant impact to our vaccination allocations."

Every state is allotted a certain number of the Johnson & Johnson, Moderna and Pfizer vaccines to distribute. About 4% of the state's vaccine supply for the week came from Johnson & Johnson. It's unclear what effect that will have for people getting vaccines in the future.

Garcetti said Los Angeles has received about 60,000 doses of the Moderna vaccine and 56,000 of the Pfizer vaccine this week.

A facility in Baltimore that was making AstraZeneca vaccines (which has also been linked to rare blood clots and is not authorized for use in the U.S.) is being investigated after it mixed up ingredients meant for the Johnson & Johnson vaccines. The New York Times reports the vaccines in circulation are not from that facility.

Still, Shafir said the news shouldn't deter those hesitant to receive the vaccine from scheduling an appointment. The AstraZeneca vaccine (which has also been linked to rare blood clots and is not authorized for use in the U.S.) and the Johnson & Johnson vaccine are adenovirus vector vaccines, while Moderna's and Pfizer's are mRNA vaccines.

Though the two effectively operate the same way once in the body, adenovirus vector vaccines introduce a weak version of the virus while mRNA vaccines introduce a peculiarly shaped protein — called the spike protein — into the body. It's similar to the coronavirus spike protein. There is no evidence that mRNA vaccines, like the Moderna and Pfizer vaccines, have produced blood clots.

"The chances someone is going to get infected with COVID and get seriously ill as a result of being infected with COVID is still multiple times higher than the chance that they will develop this very serious complication as a result of COVID vaccination," Shafir said.

This story has been updated.

https://twitter.com/KeerthiVedantam
keerthi@dot.la

Subscribe to our newsletter to catch every headline.

Office Hours: Apex Founder Ian Cinnamon on Why LA Is the Aerospace Capital of the World

Spencer Rascoff

Spencer Rascoff serves as executive chairman of dot.LA. He is an entrepreneur and company leader who co-founded Zillow, Hotwire, dot.LA, Pacaso and Supernova, and who served as Zillow's CEO for a decade. During Spencer's time as CEO, Zillow won dozens of "best places to work" awards as it grew to over 4,500 employees, $3 billion in revenue, and $10 billion in market capitalization. Prior to Zillow, Spencer co-founded and was VP Corporate Development of Hotwire, which was sold to Expedia for $685 million in 2003. Through his startup studio and venture capital firm, 75 & Sunny, Spencer is an active angel investor in over 100 companies and is incubating several more.

​Ian Cinnamon
Ian Cinnamon

On this episode of Office Hours, Apex founder and CEO Ian Cinnamon discusses the importance of investing in space exploration and shares his thoughts on the evolving space ecosystem in Los Angeles.


Read moreShow less
https://twitter.com/spencerrascoff
https://www.linkedin.com/in/spencerrascoff/
admin@dot.la

This Week in ‘Raises’: Measurabl Snags $93M, Selva Ventures Grabs $34M

Decerry Donato

Decerry Donato is a reporter at dot.LA. Prior to that, she was an editorial fellow at the company. Decerry received her bachelor's degree in literary journalism from the University of California, Irvine. She continues to write stories to inform the community about issues or events that take place in the L.A. area. On the weekends, she can be found hiking in the Angeles National forest or sifting through racks at your local thrift store.

Raises
Image by Joshua Letona

A local data management platform company lands fresh funding to help commercial real estate owners reduce carbon footprint, while one Los Angeles-based venture firm closes its second fund to accelerate the growth of emerging companies across health, wellness, beauty and personal care.

***

Read moreShow less

McKinsey & Company Launches InLA Accelerator To Help Underrepresented Founders Tackle Startup Challenges

Decerry Donato

Decerry Donato is a reporter at dot.LA. Prior to that, she was an editorial fellow at the company. Decerry received her bachelor's degree in literary journalism from the University of California, Irvine. She continues to write stories to inform the community about issues or events that take place in the L.A. area. On the weekends, she can be found hiking in the Angeles National forest or sifting through racks at your local thrift store.

McKinsey & Company Launches InLA Accelerator To Help Underrepresented Founders Tackle Startup Challenges
InLA

In 2022, female founders saw a 28% decline in overall U.S. funding, while Black-led startups saw a 38% decline in total capital received. In an effort to increase funding for minority-led startups, global venture firm McKinsey & Company is launching InLA, an accelerator program for underrepresented founders.

“This effort is something that the firm has been really excited about for a long time,” Engagement Manager Elkhyn Rivas Rodriguez said. “There's obviously a meaningful and growing startup community out here and just from a diversity standpoint, LA is incredibly diverse and multi-ethnic and multicultural. So we think that there will be a really great pool of potential companies to partner with.”

Read moreShow less
RELATEDEDITOR'S PICKS
LA TECH JOBS
interchangeLA
Trending